(R)-INCB054329 is a potent and selective inhibitor of Janus kinase 1 (JAK1), utilized in pharmaceutical research to study the inhibition of JAK1, which plays a key role in inflammatory processes and immune disorders. It is suitable for developing targeted therapies, particularly for chronic conditions requiring modulation of cytokine signaling pathways. This compound shows promise in treating rheumatoid arthritis, atopic dermatitis, and other chronic inflammatory diseases associated with the immune system. As a chiral-specific molecule, it supports advancements in precision medicine for autoimmune and inflammatory disorders, and has been evaluated in clinical trials for its selectivity and efficacy.